Review



mouse anti st2 il 33 r monoclonal antibody  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    R&D Systems mouse anti st2 il 33 r monoclonal antibody
    The effect of IL33 on the post-RT increase of Tregs in tumors. A, The time course of the IL33 level in tumor lysates from different time points (1, 6, 24, 48, and 72 hours and 7 days post RT) measured by ELISA (n = 5 per group). B, Experimental design. C57BL/6 mice were injected subcutaneously with 5 × 105 B16/F10 cells on day 0. Mice received 10 Gy of RT on day 7. Mice received a mAb to <t>ST2</t> (200 μg/ mouse, Anti-ST2 Ab) or vehicle intraperitoneally (i.p.) every 3 days, starting 1 day before RT. Tumors, DLNs, and spleens were harvested on day 14. C, Tumor growth curves of vehicle control- (dashed line) versus ST2 Ab-treated mice (solid line), with or without radiation (black or red, respectively). D, Representative flow plot of TIL-Tregs. E and F, Quantitative scatter plots of % Foxp3+ cells of tumor-infiltrating CD4+ cells (E), and the absolute number of TIL-Tregs per gram tumor weight (F) in ST2 Ab-treated versus vehicle-treated group (n = 5 per group, repeated ×2). Error bars, SEM; ***, P < 0.001; **, P < 0.01; *, P < 0.05, determined by two-way ANOVA (A, C), and an unpaired Student t test (E, F).
    Mouse Anti St2 Il 33 R Monoclonal Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 12 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse anti st2 il 33 r monoclonal antibody/product/R&D Systems
    Average 90 stars, based on 12 article reviews
    mouse anti st2 il 33 r monoclonal antibody - by Bioz Stars, 2026-03
    90/100 stars

    Images

    1) Product Images from "Stereotactic Radiotherapy Increases Functionally Suppressive Regulatory T Cells in the Tumor Microenvironment"

    Article Title: Stereotactic Radiotherapy Increases Functionally Suppressive Regulatory T Cells in the Tumor Microenvironment

    Journal: Cancer immunology research

    doi: 10.1158/2326-6066.CIR-17-0040

    The effect of IL33 on the post-RT increase of Tregs in tumors. A, The time course of the IL33 level in tumor lysates from different time points (1, 6, 24, 48, and 72 hours and 7 days post RT) measured by ELISA (n = 5 per group). B, Experimental design. C57BL/6 mice were injected subcutaneously with 5 × 105 B16/F10 cells on day 0. Mice received 10 Gy of RT on day 7. Mice received a mAb to ST2 (200 μg/ mouse, Anti-ST2 Ab) or vehicle intraperitoneally (i.p.) every 3 days, starting 1 day before RT. Tumors, DLNs, and spleens were harvested on day 14. C, Tumor growth curves of vehicle control- (dashed line) versus ST2 Ab-treated mice (solid line), with or without radiation (black or red, respectively). D, Representative flow plot of TIL-Tregs. E and F, Quantitative scatter plots of % Foxp3+ cells of tumor-infiltrating CD4+ cells (E), and the absolute number of TIL-Tregs per gram tumor weight (F) in ST2 Ab-treated versus vehicle-treated group (n = 5 per group, repeated ×2). Error bars, SEM; ***, P < 0.001; **, P < 0.01; *, P < 0.05, determined by two-way ANOVA (A, C), and an unpaired Student t test (E, F).
    Figure Legend Snippet: The effect of IL33 on the post-RT increase of Tregs in tumors. A, The time course of the IL33 level in tumor lysates from different time points (1, 6, 24, 48, and 72 hours and 7 days post RT) measured by ELISA (n = 5 per group). B, Experimental design. C57BL/6 mice were injected subcutaneously with 5 × 105 B16/F10 cells on day 0. Mice received 10 Gy of RT on day 7. Mice received a mAb to ST2 (200 μg/ mouse, Anti-ST2 Ab) or vehicle intraperitoneally (i.p.) every 3 days, starting 1 day before RT. Tumors, DLNs, and spleens were harvested on day 14. C, Tumor growth curves of vehicle control- (dashed line) versus ST2 Ab-treated mice (solid line), with or without radiation (black or red, respectively). D, Representative flow plot of TIL-Tregs. E and F, Quantitative scatter plots of % Foxp3+ cells of tumor-infiltrating CD4+ cells (E), and the absolute number of TIL-Tregs per gram tumor weight (F) in ST2 Ab-treated versus vehicle-treated group (n = 5 per group, repeated ×2). Error bars, SEM; ***, P < 0.001; **, P < 0.01; *, P < 0.05, determined by two-way ANOVA (A, C), and an unpaired Student t test (E, F).

    Techniques Used: Enzyme-linked Immunosorbent Assay, Injection



    Similar Products

    mouse anti st2 il 33 r monoclonal antibody  (R&D Systems)
    90
    R&D Systems mouse anti st2 il 33 r monoclonal antibody
    The effect of IL33 on the post-RT increase of Tregs in tumors. A, The time course of the IL33 level in tumor lysates from different time points (1, 6, 24, 48, and 72 hours and 7 days post RT) measured by ELISA (n = 5 per group). B, Experimental design. C57BL/6 mice were injected subcutaneously with 5 × 105 B16/F10 cells on day 0. Mice received 10 Gy of RT on day 7. Mice received a mAb to <t>ST2</t> (200 μg/ mouse, Anti-ST2 Ab) or vehicle intraperitoneally (i.p.) every 3 days, starting 1 day before RT. Tumors, DLNs, and spleens were harvested on day 14. C, Tumor growth curves of vehicle control- (dashed line) versus ST2 Ab-treated mice (solid line), with or without radiation (black or red, respectively). D, Representative flow plot of TIL-Tregs. E and F, Quantitative scatter plots of % Foxp3+ cells of tumor-infiltrating CD4+ cells (E), and the absolute number of TIL-Tregs per gram tumor weight (F) in ST2 Ab-treated versus vehicle-treated group (n = 5 per group, repeated ×2). Error bars, SEM; ***, P < 0.001; **, P < 0.01; *, P < 0.05, determined by two-way ANOVA (A, C), and an unpaired Student t test (E, F).
    Mouse Anti St2 Il 33 R Monoclonal Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse anti st2 il 33 r monoclonal antibody/product/R&D Systems
    Average 90 stars, based on 1 article reviews
    mouse anti st2 il 33 r monoclonal antibody - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier
    il33 signaling blockade mouse anti st2 il 33 r monoclonal antibody  (R&D Systems)
    92
    R&D Systems il33 signaling blockade mouse anti st2 il 33 r monoclonal antibody
    The effect of <t>IL33</t> on the post-RT increase of Tregs in tumors. A, The time course of the IL33 level in tumor lysates from different time points (1, 6, 24, 48, and 72 hours and 7 days post RT) measured by ELISA (n = 5 per group). B, Experimental design. C57BL/6 mice were injected subcutaneously with 5 × 105 B16/F10 cells on day 0. Mice received 10 Gy of RT on day 7. Mice received a mAb to <t>ST2</t> (200 μg/ mouse, Anti-ST2 Ab) or vehicle intraperitoneally (i.p.) every 3 days, starting 1 day before RT. Tumors, DLNs, and spleens were harvested on day 14. C, Tumor growth curves of vehicle control- (dashed line) versus ST2 Ab-treated mice (solid line), with or without radiation (black or red, respectively). D, Representative flow plot of TIL-Tregs. E and F, Quantitative scatter plots of % Foxp3+ cells of tumor-infiltrating CD4+ cells (E), and the absolute number of TIL-Tregs per gram tumor weight (F) in ST2 Ab-treated versus vehicle-treated group (n = 5 per group, repeated ×2). Error bars, SEM; ***, P < 0.001; **, P < 0.01; *, P < 0.05, determined by two-way ANOVA (A, C), and an unpaired Student t test (E, F).
    Il33 Signaling Blockade Mouse Anti St2 Il 33 R Monoclonal Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/il33 signaling blockade mouse anti st2 il 33 r monoclonal antibody/product/R&D Systems
    Average 92 stars, based on 1 article reviews
    il33 signaling blockade mouse anti st2 il 33 r monoclonal antibody - by Bioz Stars, 2026-03
    92/100 stars
    		  Buy from Supplier

    Image Search Results


    The effect of IL33 on the post-RT increase of Tregs in tumors. A, The time course of the IL33 level in tumor lysates from different time points (1, 6, 24, 48, and 72 hours and 7 days post RT) measured by ELISA (n = 5 per group). B, Experimental design. C57BL/6 mice were injected subcutaneously with 5 × 105 B16/F10 cells on day 0. Mice received 10 Gy of RT on day 7. Mice received a mAb to ST2 (200 μg/ mouse, Anti-ST2 Ab) or vehicle intraperitoneally (i.p.) every 3 days, starting 1 day before RT. Tumors, DLNs, and spleens were harvested on day 14. C, Tumor growth curves of vehicle control- (dashed line) versus ST2 Ab-treated mice (solid line), with or without radiation (black or red, respectively). D, Representative flow plot of TIL-Tregs. E and F, Quantitative scatter plots of % Foxp3+ cells of tumor-infiltrating CD4+ cells (E), and the absolute number of TIL-Tregs per gram tumor weight (F) in ST2 Ab-treated versus vehicle-treated group (n = 5 per group, repeated ×2). Error bars, SEM; ***, P < 0.001; **, P < 0.01; *, P < 0.05, determined by two-way ANOVA (A, C), and an unpaired Student t test (E, F).

    Journal: Cancer immunology research

    Article Title: Stereotactic Radiotherapy Increases Functionally Suppressive Regulatory T Cells in the Tumor Microenvironment

    doi: 10.1158/2326-6066.CIR-17-0040

    Figure Lengend Snippet: The effect of IL33 on the post-RT increase of Tregs in tumors. A, The time course of the IL33 level in tumor lysates from different time points (1, 6, 24, 48, and 72 hours and 7 days post RT) measured by ELISA (n = 5 per group). B, Experimental design. C57BL/6 mice were injected subcutaneously with 5 × 105 B16/F10 cells on day 0. Mice received 10 Gy of RT on day 7. Mice received a mAb to ST2 (200 μg/ mouse, Anti-ST2 Ab) or vehicle intraperitoneally (i.p.) every 3 days, starting 1 day before RT. Tumors, DLNs, and spleens were harvested on day 14. C, Tumor growth curves of vehicle control- (dashed line) versus ST2 Ab-treated mice (solid line), with or without radiation (black or red, respectively). D, Representative flow plot of TIL-Tregs. E and F, Quantitative scatter plots of % Foxp3+ cells of tumor-infiltrating CD4+ cells (E), and the absolute number of TIL-Tregs per gram tumor weight (F) in ST2 Ab-treated versus vehicle-treated group (n = 5 per group, repeated ×2). Error bars, SEM; ***, P < 0.001; **, P < 0.01; *, P < 0.05, determined by two-way ANOVA (A, C), and an unpaired Student t test (E, F).

    Article Snippet: Mouse anti-ST2/IL-33 R monoclonal antibody (Clone 245707, R&D) was diluted in PBS and administrated intraperitoneally at a concentration of 200 μg in a volume of 100 μL per mouse every 3 days ( 25 ), starting 1 day before RT, for a total of three doses.

    Techniques: Enzyme-linked Immunosorbent Assay, Injection

    The effect of IL33 on the post-RT increase of Tregs in tumors. A, The time course of the IL33 level in tumor lysates from different time points (1, 6, 24, 48, and 72 hours and 7 days post RT) measured by ELISA (n = 5 per group). B, Experimental design. C57BL/6 mice were injected subcutaneously with 5 × 105 B16/F10 cells on day 0. Mice received 10 Gy of RT on day 7. Mice received a mAb to ST2 (200 μg/ mouse, Anti-ST2 Ab) or vehicle intraperitoneally (i.p.) every 3 days, starting 1 day before RT. Tumors, DLNs, and spleens were harvested on day 14. C, Tumor growth curves of vehicle control- (dashed line) versus ST2 Ab-treated mice (solid line), with or without radiation (black or red, respectively). D, Representative flow plot of TIL-Tregs. E and F, Quantitative scatter plots of % Foxp3+ cells of tumor-infiltrating CD4+ cells (E), and the absolute number of TIL-Tregs per gram tumor weight (F) in ST2 Ab-treated versus vehicle-treated group (n = 5 per group, repeated ×2). Error bars, SEM; ***, P < 0.001; **, P < 0.01; *, P < 0.05, determined by two-way ANOVA (A, C), and an unpaired Student t test (E, F).

    Journal: Cancer immunology research

    Article Title: Stereotactic Radiotherapy Increases Functionally Suppressive Regulatory T Cells in the Tumor Microenvironment

    doi: 10.1158/2326-6066.CIR-17-0040

    Figure Lengend Snippet: The effect of IL33 on the post-RT increase of Tregs in tumors. A, The time course of the IL33 level in tumor lysates from different time points (1, 6, 24, 48, and 72 hours and 7 days post RT) measured by ELISA (n = 5 per group). B, Experimental design. C57BL/6 mice were injected subcutaneously with 5 × 105 B16/F10 cells on day 0. Mice received 10 Gy of RT on day 7. Mice received a mAb to ST2 (200 μg/ mouse, Anti-ST2 Ab) or vehicle intraperitoneally (i.p.) every 3 days, starting 1 day before RT. Tumors, DLNs, and spleens were harvested on day 14. C, Tumor growth curves of vehicle control- (dashed line) versus ST2 Ab-treated mice (solid line), with or without radiation (black or red, respectively). D, Representative flow plot of TIL-Tregs. E and F, Quantitative scatter plots of % Foxp3+ cells of tumor-infiltrating CD4+ cells (E), and the absolute number of TIL-Tregs per gram tumor weight (F) in ST2 Ab-treated versus vehicle-treated group (n = 5 per group, repeated ×2). Error bars, SEM; ***, P < 0.001; **, P < 0.01; *, P < 0.05, determined by two-way ANOVA (A, C), and an unpaired Student t test (E, F).

    Article Snippet: IL33 signaling blockade Mouse anti-ST2/IL-33 R monoclonal antibody (Clone 245707, R&D) was diluted in PBS and administrated intraperitoneally at a concentration of 200 μg in a volume of 100 μL per mouse every 3 days ( 25 ), starting 1 day before RT, for a total of three doses.

    Techniques: Enzyme-linked Immunosorbent Assay, Injection